Ikarian Capital’s IGM Biosciences IGMS Stock Holding History

Ikarian Capital’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,587	Closed	-$43K	–	168
2022 Q1	$43K	Buy	1,587 +87	+6%	+$1.62K	0.01%	186
2021 Q4	$44K	Sell	1,500 -50,000	-97%	-$2.48M	0.01%	174
2021 Q3	$3.39M	Buy	+51,500	New	+$3.94M	0.24%	93
2021 Q2	–	Sell	-300	Closed	-$23K	–	244
2021 Q1	$23K	Hold	300	–	–	﹤0.01%	287
2020 Q4	$27K	Buy	+300	New	+$21.1K	﹤0.01%	223

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ikarian Capital's IGMS Position: Q2 2022 in Review

Ikarian Capital sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 1,587 shares — an estimated $43K sold.

Ikarian Capital first reported a position in IGMS in Q4 2020 and held it in 5 quarters. The position peaked at $3.39M in Q3 2021. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

Ikarian Capital reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 1,587 IGM Biosciences shares in Q2 2022, an estimated $43K.
Ikarian Capital first reported a position in IGM Biosciences in Q4 2020 and held it in 5 quarters.
Ikarian Capital's IGM Biosciences position peaked at $3.39M in Q3 2021.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.